(2) To exclude herself from serving in any advisory capacity to the Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. Dr. London is required to submit a letter to

- *Chemical Senses* requesting a retraction of the following article: London, J.A. ''Optical recording of activity in the hamster gustatory cortex elicited by electrical stimulation of the tongue.'' *Chemical Senses* 15:137–143, 1990;
- *Brain Research* requesting a retraction of the following article: London, J.A., & Wehby, R.G. ''Classification of inhibitory responses of the hamster gustatory cortex.'' *Brain Research* 666:270–274, 1994; and
- *Optical Methods in Neurobiology* requesting a retraction of Section V, Results—Hamster of the following article: London, J.A., & Cohen, L.B. ''High time resolution, multi-site optical measurement of vertebrate somatosensory cortex during epileptiform discharges and vertebrate gustatory cortex.'' *Optical Methods in Neurobiology*, pp. 61–78, 1988, prepared for the 11th Annual Meeting of the European Neuroscience Association.

FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Acting Director, Office of Research Integrity.

[FR Doc. 97–22081 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–17–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97F–0301]

Ube Industries (America), Inc.; Filing of Food Additive Petition; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of July 21, 1997 (62 FR 39003). The document announced that Ube Industries (America), Inc., filed a petition proposing that the food additive regulations be amended to change the melting point range specifications for Nylon 6/66 resins intended for use in contact with food. The document published with an incorrect docket number. This document corrects that error.

FOR FURTHER INFORMATION CONTACT: Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS–215), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3081.

In FR Doc. 97–19127, appearing on page 39003 in the **Federal Register** of Monday, July 21, 1997, the following correction is made:

1. On page 39003, in the first column, Docket No. ''97N–0301'' is corrected to read ''97F–0301''.

Dated: August 13, 1997.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 97–22091 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Anesthetic and Life Support Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on September 17, 1997, 8 a.m. to 5 p.m.

Location: Gaithersburg Hilton, Grand Ballroom, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: Karen M. Templeton-Somers or Robin M. Spencer, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–5455, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12529. Please call the Information Line for up-to-date information on this meeting.

Agenda: The committee will hear presentations and discuss data submitted regarding new drug application (NDA) 20–747, Actiq™ (oral transmucosal fentanyl citrate, drug matrix on a handle), Anesta Corp., for the management of chronic pain, particularly breakthrough pain, in patients who are already receiving and are tolerant to opioid therapy.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 4, 1997. Oral presentations from the public will be scheduled between approximately 8 a.m. and 8:30 a.m. and 3 p.m. and 3:30 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 4, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 14, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–22090 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Blood Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on September 18, 1997, 8 a.m. to 5:30 p.m., and September 19, 1997, 8 a.m. to 4 p.m.

Location: Quality Suites Hotel, Potomac Rooms I, II, and III, Three Research Ct. (off Shady Grove Rd.), Rockville, MD.

Contact Person: Linda A. Smallwood, Center for Biologics Evaluation and Research (HFM–350), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–3514, or FDA Advisory Committee Information

Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12388. Please call the Information Line for up-to-date information on this meeting.

Agenda: On the morning of September 18, 1997, the committee will discuss the topic of inadvertent contamination of plasma. In the afternoon, the committee will hear a proposal for management of plasma and plasma donors presented by the International Plasma Products Industry Association. On September 19, 1997, the committee will discuss the topic of cryoprecipitate-depleted plasma.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 10, 1997. Oral presentations from the public will be scheduled between approximately 11 a.m. and 11:30 a.m. and 2 p.m. and 3 p.m. on September 18, 1997. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 10, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 14, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–22088 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Circulatory System Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on September 15, 1997, 9:30 a.m. to 6 p.m., and September 16, 1997, 8:30 a.m. to 3 p.m.

Location: Gaithersburg Hilton, Salons A, B, and C of the Ballroom, 620 Perry Pkwy., Gaithersburg, MD.

Contact Person: John E. Stuhlmuller, Center for Devices and Radiological Health (HFZ–450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–443–8243, ext. 157, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12625. Please call the Information Line for up-to-date information on this meeting.

Agenda: On September 15, 1997, the committee will hear a presentation of the basic concepts of FDA's Product Development Process. The committee will discuss and make recommendations on two premarket approval (PMA) applications for prosthetic heart valves. On September 16, 1997, the committee will discuss and make recommendations on a PMA for a prosthetic heart valve.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by September 5, 1997. Oral presentations from the public will be scheduled between approximately 9:30 a.m. and 10:30 a.m. on September 15, 1997, and between approximately 8:30 a.m. and 9:30 a.m. on September 16, 1997. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before September 5, 1997, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: August 14, 1997.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 97–22089 Filed 8–19–97; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[Form #HCFA–1500, OMB #0938–0008]

Emergency Clearance: Public Information Collection Requirements Submitted to the Office of Management and Budget (OMB)

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services (DHHS), has submitted to the Office of Management and Budget (OMB) the following request for Emergency review. We are requesting an emergency review because the collection of this information is needed prior to the expiration of the normal time limits under OMB's regulations at 5 CFR Part 1320. The HCFA–1500 is used to determine proper payment for certain Medicare services rendered to Medicare beneficiaries. Without this information HCFA would not be able to obtain the information necessary to reimburse providers. The Agency cannot reasonably comply with the normal clearance procedures because public harm is likely to result due to the possibility of providers not rendering services to Medicare beneficiaries due to the possibility of non-payment.

HCFA is requesting OMB review and approval of this collection by 09/01/97, with a 180-day approval period. During this 180-day period HCFA will publish a separate **Federal Register** notice announcing the initiation of an extensive 60-day agency review and public comment period on these requirements. Then HCFA will submit the requirements for OMB review and an extension of this emergency approval. In this submission HCFA will respond as appropriate to the public comments received in response to the 10/24/97 **Federal Register** notice requesting public comment on the continued use of the HCFA–1500 and related data.

1. *Type of Information Collection Request:* Extension of a currently approved collection, without change; *Title of Information Collection:* Medicare/Medicaid Health Insurance Common Claim Form and Instructions, and Supporting Regulations 42 CFR 424.32 (Basic Requirements for all Claims) and 42 CFR 414.40 (Coding and Ancillary Policies); *Form No.:* HCFA–1500 (OMB #0938–0008); *Use:* This form and instructions are standardized for use in the Medicare/Medicaid programs to apply for reimbursement for covered